[CH:1]1([NH:6][C:7]2[CH:12]=[CH:11][N:10]3[N:13]=[C:14]([C:28]4[CH:33]=[CH:32][C:31]([F:34])=[CH:30][CH:29]=4)[C:15]([C:16]4[CH:21]=[CH:20][N:19]=[C:18]([NH:22][CH:23]5[CH2:27][CH2:26][CH2:25][CH2:24]5)[N:17]=4)=[C:9]3[CH:8]=2)[CH2:5][CH2:4][CH2:3][CH2:2]1.[Br:35]N1C(=O)CCC1=O.[OH-].[Na+]>ClCCl>[Br:35][C:8]1[C:9]2[N:10]([N:13]=[C:14]([C:28]3[CH:29]=[CH:30][C:31]([F:34])=[CH:32][CH:33]=3)[C:15]=2[C:16]2[CH:21]=[CH:20][N:19]=[C:18]([NH:22][CH:23]3[CH2:24][CH2:25][CH2:26][CH2:27]3)[N:17]=2)[CH:11]=[CH:12][C:7]=1[NH:6][CH:1]1[CH2:2][CH2:3][CH2:4][CH2:5]1N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-fluorophenyl)pyrazolo-[1,5-α]pyridin-5-amine (100 mg, 0.22 mmol) was dissolved in dichloromethane (5 mL) and treated with N-bromosuccinimide (40 mg, 0.22 mmol). The reaction mixture was stirred for 10 minutes. Additional dichloromethane and 1N aqueous sodium hydroxide was added. The phases were separated, the organic phase washed with water, dried (magnesium sulfate), filtered and concentrated to dryness to give 100 mg of the title compound as a yellow foam. 1H NMR (CDCl3): δ 8.32 (d, 1H), 8.22 (d, 1H), 7.53 (q, 2H), 7.04 (t, 2H), 6.53 (m, 2H), 5.17 (d, 1H), 4.72 (d, 1H), 4.33 (m, 1H), 3.95 (m, 1H), 2.1–1.4 (m, 16H); 19F NMR (CDCl3): δ −113.97; MS m/z 536 (M+1).